Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3597]

ESMO 2016: Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

ESMO 2016: Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

‘Game-changing’ immunotherapy doubles head and neck cancer survival

‘Game-changing’ immunotherapy doubles head and neck cancer survival

ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

ESMO 2016: Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

ESMO 2016: Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

ESMO 2016: Combination therapy shows higher response and lower toxicity in paediatric brain cancer trial

ESMO 2016: Combination therapy shows higher response and lower toxicity in paediatric brain cancer trial

ESMO 2016: Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

ESMO 2016: Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer

Antibody drug conjugates may help personalise radiotherapy for patients with cancer

Antibody drug conjugates may help personalise radiotherapy for patients with cancer

Bladder cancer research rife with new approaches

Bladder cancer research rife with new approaches

ESMO 2016: Reporting of adverse events in targeted therapy and immunotherapy trials is “suboptimal”

ESMO 2016: Reporting of adverse events in targeted therapy and immunotherapy trials is “suboptimal”

New research indicates key protein may directly impact development of colon cancer

New research indicates key protein may directly impact development of colon cancer

More from ecancer